Aclarion added to the PRISM Emerging Medical Devices index

Industry-first technology from the company solves chronic lower back pain
Aclarion Signs First Commercial Agreement with Michigan’s Sheridan Community Hospital
The PRISM Emerging Medical Devices Index highlights companies at the forefront of innovation and market disruption in medical technology.

NEW YORK, Sept. 6, 2024 (GLOBE NEWSWIRE) — PRISM MarketView, a leading provider of market intelligence and company news, is pleased to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which recognizes companies at the forefront of innovation and market disruption in the medical technology sector. Aclarion’s innovative AI-based diagnostic solutions for chronic lower back pain distinguish the company in the emerging medical device sector.

The U.S. medical device market is expected to grow significantly, reaching an estimated value of nearly $315 billion by 2032. This expansion is being driven by increasing investment in research and development and a solid pipeline of innovations, including Aclarion’s NOCISCAN technology, which offers the first noninvasive, AI-assisted diagnostic tool to identify painful discs in patients with chronic lower back pain.

Low back pain is one of the largest healthcare expenses in the United States, with the market for low back pain diagnostics and treatment estimated at $40 billion annually and total costs of $134.5 billion. Aclarion’s NOCISCAN technology addresses this growing need by offering a noninvasive diagnostic alternative.

Aclario Key Features:

The industry’s first non-invasive diagnosticsAclarion’s NOCISCAN technology is a first-of-its-kind technology that provides a non-invasive alternative to traditional diagnostics and delivers improved surgical outcomes for patients suffering from lower back pain.
Strong market validation: Aclarion addresses one of the world’s largest and most costly healthcare challenges—degenerative spine disease and lower back pain, which affects 266 million patients worldwide. The company’s proven technology, along with newly established regulatory pathways and payer reach, paves the way for broader global adoption and drives strong market validation.
Partnerships and Agreements: Aclarion has secured its first commercial agreement in Michigan with Sheridan Community Hospital, bringing NOCISCAN to central Michigan. Additionally, the company has expanded its commercial agreement with The London Clinic, expanding access throughout the London market. Aclarion has also secured private payer insurance from major U.K. insurers, including AXA, Aviva and Vitality, providing access to 60% of private health insurance patients in Greater London. Yesterday, the company announced the launch of a program to develop a statewide provider network in New Jersey to leverage NOCISCAN across the entire personal injury and workers’ compensation population.
Clinical evidence:Aclarion’s technology is supported by strong clinical data, showing an 85% improvement in patients treated with NOCISCAN. There are several ongoing clinical trials, including the CLARITY trial, which is expected to enroll up to 300 patients. Patient enrollment is expected to begin in Q4 2024, with interim data available by Q1 2026 and full data by Q2 2026. The company is actively conducting additional studies to further validate the efficacy of its technology.

For more information about Aclarion and the PRISM Emerging Medical Devices Index, visit prismmarketview.com.

About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatment. The company is pioneering the chronic low back pain market with NOCISCAN, the first evidence-based SaaS platform that noninvasively helps physicians differentiate between painful and non-painful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy data from an MRI machine for each lumbar disc being examined. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers that have been shown to be associated with disc pain. The biomarker data is fed into proprietary algorithms to indicate whether a disc may be the source of pain. When combined with other diagnostic tools, NOCISCAN provides critical information on the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, visit www.aclarion.com.

About PRISM MarketView
Founded in 2020, PRISM MarketView tracks and analyzes small-cap stocks in emerging sectors. We provide breaking financial news, comprehensive investor tools, and a vibrant investment community. At the heart of our offering are proprietary indices that track emerging sectors including biotech, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.

PRISM Market View does not provide investment advice.

Reservation: This communication was prepared by PRISM MarketView, a subsidiary of PCG Advisory Inc. (collectively, “PCG”). PCG is not a registered or licensed broker-dealer or investment advisor. Nothing in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation for any securities. PCG may receive compensation from relevant clients for publishing information regarding their clients’ securities. See www.pcgadvisory.com/disclosures.

Contact:  
PRISM Market View
[email protected]
646-863-6341

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a4c45b4-63ec-4049-a7b8-16369cff9c9a